Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT00099502
Ignite Creation Date: 2024-05-05 @ 11:38 AM
Last Modification Date: 2024-10-26 @ 9:11 AM
Study NCT ID: NCT00099502
Protocol Section: NCT00099502
Start Identification Module Data
Expand Identification Module Data
Brief Title: BEYOND BetaferonBetaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis MS Patients
Official Title: International Randomized Multicenter Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks 1 Double-Blinded Safety Tolerability and Efficacy of Betaseron Betaferon 250 µg 8 MIU and Betaseron-Betaferon 500 µg 16 MIU Both Given Subcutaneously Every Other Day and 2 Rater-Blinded Safety Tolerability and Efficacy of Betaseron-Betaferon sc Every Other Day With Copaxone 20 mg sc Once Daily
Acronym: None
Organization: Bayer
Organization Class: INDUSTRY
Organization Study ID: 91162
Secondary IDs
Secondary ID Type Domain Link
EudraCT 2005-002235-27 None None None
306440 None None None
Beyond None None None
Start Status Module Data
Status Verified Date: 2008-12
Overall Status: COMPLETED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Bayer
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Bayer
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload